Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Methodology of a Novel Risk Stratification Algorithm for Patients with Multiple Myeloma in the Relapsed Setting

W. Bouwmeester, A. Briggs, B. van Hout, R. Hájek, S. Gonzalez-McQuire, M. Campioni, L. DeCosta, L. Brozova,

. 2019 ; 7 (2) : 141-157. [pub] 20191103

Jazyk angličtina Země Nový Zéland

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc20022150

INTRODUCTION: Risk stratification tools provide valuable information to inform treatment decisions. Existing algorithms for patients with multiple myeloma (MM) were based on patients with newly diagnosed disease, and these have not been validated in the relapsed setting or in routine clinical practice. We developed a risk stratification algorithm (RSA) for patients with MM at initiation of second-line (2L) treatment, based on data from the Czech Registry of Monoclonal Gammopathies. METHODS: Predictors of overall survival (OS) at 2L treatment were identified using Cox proportional hazards models and backward selection. Risk scores were obtained by multiplying the hazard ratios for each predictor. The K-adaptive partitioning for survival (KAPS) algorithm defined four groups of stratification based on individual risk scores. RESULTS: Performance of the RSA was assessed using Nagelkerke's R2 test and Harrell's concordance index through Kaplan-Meier analysis of OS data. Prognostic groups were successfully defined based on real-world data. Use of a multiplicative score based on Cox modeling and KAPS to define cut-off values was effective. CONCLUSION: Through innovative methods of risk assessment and collaboration between physicians and statisticians, the RSA was capable of stratifying patients at 2L treatment by survival expectations. This approach can be used to develop clinical decision-making tools in other disease areas to improve patient management. FUNDING: Amgen Europe GmbH.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20022150
003      
CZ-PrNML
005      
20201204094126.0
007      
ta
008      
201125s2019 nz f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s40487-019-00100-5 $2 doi
035    __
$a (PubMed)32699987
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a nz
100    1_
$a Bouwmeester, Walter $u Pharmerit International, Rotterdam, The Netherlands. wbouwmeester@pharmerit.com.
245    10
$a Methodology of a Novel Risk Stratification Algorithm for Patients with Multiple Myeloma in the Relapsed Setting / $c W. Bouwmeester, A. Briggs, B. van Hout, R. Hájek, S. Gonzalez-McQuire, M. Campioni, L. DeCosta, L. Brozova,
520    9_
$a INTRODUCTION: Risk stratification tools provide valuable information to inform treatment decisions. Existing algorithms for patients with multiple myeloma (MM) were based on patients with newly diagnosed disease, and these have not been validated in the relapsed setting or in routine clinical practice. We developed a risk stratification algorithm (RSA) for patients with MM at initiation of second-line (2L) treatment, based on data from the Czech Registry of Monoclonal Gammopathies. METHODS: Predictors of overall survival (OS) at 2L treatment were identified using Cox proportional hazards models and backward selection. Risk scores were obtained by multiplying the hazard ratios for each predictor. The K-adaptive partitioning for survival (KAPS) algorithm defined four groups of stratification based on individual risk scores. RESULTS: Performance of the RSA was assessed using Nagelkerke's R2 test and Harrell's concordance index through Kaplan-Meier analysis of OS data. Prognostic groups were successfully defined based on real-world data. Use of a multiplicative score based on Cox modeling and KAPS to define cut-off values was effective. CONCLUSION: Through innovative methods of risk assessment and collaboration between physicians and statisticians, the RSA was capable of stratifying patients at 2L treatment by survival expectations. This approach can be used to develop clinical decision-making tools in other disease areas to improve patient management. FUNDING: Amgen Europe GmbH.
655    _2
$a časopisecké články $7 D016428
700    1_
$a Briggs, Andrew $u Institute of Health and Wellbeing, University of Glasgow, Glasgow, UK.
700    1_
$a van Hout, Ben $u Department of Health Economics and Decision Science, University of Sheffield, Sheffield, UK.
700    1_
$a Hájek, Roman $u Department of Hematooncology, University Hospital Ostrava, Ostrava-Poruba, Czech Republic.
700    1_
$a Gonzalez-McQuire, Sebastian $u Amgen (Europe) GmbH, Rotkreuz, Switzerland.
700    1_
$a Campioni, Marco $u Amgen (Europe) GmbH, Rotkreuz, Switzerland.
700    1_
$a DeCosta, Lucy $u Amgen Ltd, Uxbridge, UK.
700    1_
$a Brozova, Lucie $u Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
773    0_
$w MED00205578 $t Oncology and therapy $x 2366-1089 $g Roč. 7, č. 2 (2019), s. 141-157
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32699987 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20201125 $b ABA008
991    __
$a 20201204094124 $b ABA008
999    __
$a ind $b bmc $g 1591852 $s 1112822
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 7 $c 2 $d 141-157 $e 20191103 $i 2366-1089 $m Oncology and therapy $n Oncol Ther $x MED00205578
LZP    __
$a Pubmed-20201125

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace